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Abstract 
Aim: Patients with open-angle glaucoma (OAG) whose intraocular pressure was not adequately 
controlled by one medication have several treatment options in the US. This analysis evaluated 
direct costs of unilateral eye treatment with two trabecular micro-bypass stents (two iStents) 
compared to selective laser trabeculoplasty (SLT) or medications only.  
Materials and Methods: A population-based, annual state-transition, probabilistic, cost-of-care 
model was used to assess OAG-related costs over 5 years. Patients were modeled to initiate 
treatment in year zero with two iStents, SLT, or medications only. In years 1 through 5, patients 
could remain on initial treatment or move to another treatment option(s), or filtration surgery. 
Treatment strategy change probabilities were identified by a clinician panel. Direct costs were 
included for drugs, procedures, and complications.  
Results: The projected average cumulative cost at 5 years was lower in the two-stent treatment 
arm ($4,420) compared to the SLT arm ($4,730) or medications-only arm ($6,217). Initial year-
zero costs were higher with two iStents ($2,810) than with SLT ($842) or medications only 
($996). Average marginal annual costs in years 1 through 5 were $322 for two iStents, $777 for 
SLT, and $1,044 for medications only. The cumulative cost differences between two iStents 
versus SLT or medications only decreased over time, with breakeven by 5 or 3 years post-
initiation, respectively. By year 5, cumulative savings with two iStents over SLT or medications 
only was $309 or $1,797, respectively.  
Limitations: This analysis relies on clinical expert panel opinion and would benefit from real-
world evidence on use of multiple procedures and treatment switching after two-stent treatment, 
SLT, or polypharmaceutical initial approaches. 
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Conclusions: Despite higher costs in year zero, annual costs thereafter were lowest in the two-
stent treatment arm. Two-stent treatment may reduce OAG-related health resource use, leading 
to direct savings, especially over medications only or at longer time horizons. 
 
Keywords: glaucoma, iStent, stent, trabeculoplasty, surgery, medication, intraocular pressure, 
cost, economics, health economics 
 
Short title: Cost-Analysis of Two Trabecular Micro-Bypass Stents 
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Introduction 
Glaucoma, which affects approximately 60 million people worldwide and more than 2.2 million 
people in the United States, is the second leading cause of blindness globally. Global trends 
show a growing prevalence of total glaucoma and open angle glaucoma (OAG) worldwide.1,2.  
The most important risk factor for glaucoma is elevated intraocular pressure (IOP). Thus, a 
central goal of all glaucoma therapy is IOP reduction.3,4 The management of patients with OAG 
should take into account the risks associated with therapy and other factors such as age, disease 
severity, comorbidities, tolerability of medications, desired post-operative IOP and cost.5-7 
Treatment options for OAG have traditionally included medical therapy, laser trabeculoplasty, 
incisional glaucoma procedures, and cyclodestructive surgery.8 Topical eye drops require 
adherence from patients and are not always well-tolerated. Laser therapy such as Selective Laser 
Trabeculoplasty (SLT) can provide a clinically significant reduction of IOP. Among OAG 
patients who range from newly diagnosed to those on maximally tolerated medical therapy, SLT 
results in a 6.9 - 35.9% intraocular pressure (IOP) reduction and complications are rare.9  
However, the long-term results are questionable, as failure rates have been reported in the range 
of 33-74%.9-11 
 
The introduction of Micro-Invasive Glaucoma Surgery (MIGS) implants offers a viable 
alternative for patients with mild to moderate OAG.  iStent (Glaukos Corporation, Laguna Hills, 
CA, USA), one of the first and most commonly used MIGS devices, is a heparincoated, non-
ferromagnetic, titanium stent 1 mm in length and 0.3 mm in height. The iStent Trabecular Micro-
Bypass is a ‘first in class’ MIGS device that addresses mild to moderate open-angle glaucoma, 
thereby potentially filling an important gap in the current treatment algorithm for glaucoma.3 The 
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stent is designed to cannulate Schlemm’s canal and create a communication from this space 
directly to the anterior chamber, allowing aqueous humour to egress into Schlemm’s canal more 
easily, thereby lowering IOP.  
Understanding whether one of these treatment options confers a greater value relative to the 
other is important for many different stakeholders including health care policy makers, third-
party payers, eye providers, and most importantly, patients. With the dramatically increasing 
costs of health care in the United States, it is essential to find ways to curtail costs, ideally 
without sacrificing the quality of care provided. This analysis evaluated the direct costs in the 
United States of unilateral eye treatment with two trabecular micro-bypass stents (two iStents) 
compared to selective laser trabeculoplasty (SLT) or medications only over 5 years post-
initiation. 
 
Methods 
An analysis of the cost impact of using the iStent device for treatment of patients whose OAG 
was not adequately controlled by one medication was built as a Markov model using TreeAge 
modeling software. The analysis was a payer-perspective, population-based, state-transition, 
probabilistic, cost-of-care model with an annual cycle and a 5-year time horizon. Direct costs 
were considered for OAG-related drugs, procedures, and complications for the treated eye. Three 
treatment arms were included in the analysis. Initiating treatment with an iStent procedure was 
compared to two alternate current treatment options: initiating treatment with an SLT procedure, 
or initiating treatment with medications alone. 
 
Treatment transition probabilities 
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Treatment switching and other downstream filtering surgery procedures were permitted in the 
analysis in subsequent years (after 1 year post-initiation) (Figure 1). Filtering surgery procedures 
considered included trabeculectomy, aqueous shunt, and ab externo drainage device without an 
extraocular reservoir (Current Procedural Terminology [CPT] codes 66170; 66180 with or 
without 67225; and 66183 respectively); these procedures were selected and their distribution 
identified based on an analysis of the 2013 CMS Standard Analytical File. For each treatment 
arm in each cycle, the probabilities of downstream procedures, and the probabilities and numbers 
of concurrent medications were identified by a panel of clinicians experienced in the care of 
patients with glaucoma (Table 1). In establishing these probabilities, panel discussion 
acknowledged and accounted for the difference between effectiveness as reported in clinical 
trials and effectiveness observed in real-world settings where patient circumstance and adherence 
to medication were less controlled and more varied. 
 
Medications use 
Medications considered in this analysis were prostaglandins, beta-blockers, carbonic anhydrase 
inhibitors, and alpha adrenergic agonists (Table 2). The analysis allowed for treatment with a 
mix of medications only, and for concurrent medication(s) use with downstream iStents, SLT, or 
filtering surgery procedures. During each cycle, patients being treated with iStents, SLT, or 
filtering procedures could have 0 to 4 concurrent medications, and patients being treated with 
medications-only treatment could have 2 to 4 concurrent medications. The market shares for 
drug manufacturers (branded and/or generic) within each class of drug were from 2014 IMS 
data. 
 
Direct costs 
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Drug acquisition costs were from 2016 RED BOOK. Drug dosages from package inserts for each 
drug were applied. Calculations for liquid mediation use rate assumed 20 drops per mL based on 
previously published analyses of glaucoma drug costs and liquid medications wastage with 
patient administration.11-13 These data along with medications use treatment patterns were used 
to derive the annual costs for glaucoma medications (Table 3). 
Costs of procedures were from the 2016 Outpatient Prospective Payment System (OPPS) 
Limited Data Set (LDS) (Table 3). Complication costs were $0 for both the iStent and SLT 
procedures based on published literature that demonstrated that complications risks with either 
were very low.14-16 Complications costs with filtering surgeries were based on an analysis of the 
2013 CMS Standard Analytical File. All costs are reported in 2016 US dollars using the 
consumer price indices reported by the US Bureau of Labor Statistics.17 Later-year costs were 
discounted to year 0 using an annual time preference discount rate of 3% in accordance with the 
Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials report by the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR).18 
 
Sensitivity analyses 
One-way sensitivity analyses were conducted to assess the effect of input uncertainty on the 
model’s results. Each input was varied across a range of values, and the resulting changes in the 
modeled 5-year cumulative costs were evaluated. Complication costs for all years were varied 
together for each treatment. Complication costs with the SLT procedure or the iStent procedure 
were varied between zero (basecase), and 50% of the basecase complication costs with filtering 
surgery (Table 3). Medication costs were varied together as a group by ±25%. The annual time 
preference discount rate was varied between 1% and 5% in accordance with ISPOR guidelines. 
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The probability of downstream procedures (SLT, filtering surgery, or iStent procedure) after 
initial treatment in each treatment arm was varied by ±50%. All other cost variables were 
adjusted independently by ±25%. The maximum variation in results due to inputs uncertainty 
was identified, as were the inputs whose uncertainty range most influenced the results. 
 
Results 
The cumulative total costs over 5 years for patients initiating treatment with medications only, 
SLT, and iStent procedures were $6,217.08, $4,729.85, and $4,420.38 per patient on average, 
respectively (Figure 2). Cumulative cost-savings over 5 years with the iStent procedure 
compared to medications only was estimated at $1,796.70 per patient on average. The 
cumulative cost with the iStent procedure was approximately equivalent to SLT only at 5 years 
($309.47 lower with the iStent procedure). 
 
Of the three treatment options, the initial year 0 cost was highest with the iStent procedure, due 
to initial device acquisition cost and lowest with SLT. These were offset by the annual marginal 
costs after initial treatment (years 1-5), which were lowest with the iStent procedure, and highest 
with medications only (Table 4). Costs in each year following SLT or medications only initial 
treatments were more than double that of the iStent procedure. In the first following year (year 
1), the annual marginal cost was 3.2 times higher with SLT, and 4.9 times higher with 
medications only, compared to the iStent procedure. 
 
One-way sensitivity analyses identified the variables whose uncertainty most influenced the 
results (Table 5). These demonstrated that the cost of the iStent procedure, cost of medications, 
and probability of downstream procedures in the SLT procedure arm were the variables whose 
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uncertainty most influenced the cost-comparison between the iStent procedure and SLT (Figure 
3a). For the cost-comparison between the iStent procedure and medications-only, the variables 
whose uncertainty had the most effect were the cost of medications, cost of the iStent procedure, 
and probability of downstream procedures in the iStent procedure arm (Figure 3b). 
 
Discussion 
Medications cumulative costs following initial treatment with the iStent procedure is cost-saving 
compared to initial treatment with medications-only by year 3. The cumulative cost-savings 
continue to increase in subsequent years.  SLT cumulative costs with initial treatment with the 
iStent procedure reaches breakeven with initial SLT treatment between years 4 and 5, despite 
higher costs in year 0 with the iStent procedure. In combination with the lower annual marginal 
costs in years 1-5 after iStent procedure compared to medications-only initial treatment 
strategies, this suggests that analyses with longer time horizons than 5 years may show the iStent 
procedure to be increasingly cost-saving compared to SLT. Further research is needed to test 
these expectations and confirm these results in real-world settings.  Despite higher costs in year 
zero, annual costs thereafter were lowest in the two-stent treatment arm.  Five-year cumulative 
costs in the two-stent treatment arm were approximately equivalent to the SLT arm, and showed 
savings compared to the medications only arm.  Two-stent treatment may reduce OAG-related 
health resource use, leading to direct savings, especially over medications only or at longer time 
horizons. 
 
There are several study limitations that need to be acknowledged.  While we were able to 
identify reasonable estimates of cost, in the absence of long-term comparative data, treatment 
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transition probabilities were determined by a panel of clinicians experienced in the treatment of 
glaucoma. These probabilities are based in years of clinical experience but are still theoretical. 
These inputs, and therefore this analysis, could be strengthened with real-world evidence. For all 
model assumptions, we were able to use one-way sensitivity analyses to examine the impact of 
changing the assumptions on the findings.  The probability of downstream procedures (SLT, 
filtering surgery, or iStent procedure) after initial treatment in each treatment arm was varied by 
±50% (Figure 3).  Even with this high range, the results remain relatively stable.  
 
In addition, mortality was not considered in this 5 year model because glaucoma patients 
regardless of treatment have similar mortality rates.  Also, only direct medical costs were 
considered.  Glaucoma has a significant impact on HRQoL even in the early stages of disease.19 
HRQoL reflects a person's wellbeing and focuses on dimensions of physical functioning, social 
functioning, mental health, and general health perceptions. Ongoing visual field loss can impair 
patients' abilities to perform common daily activities (e.g., driving, walking, and reading). Vision 
loss may impose an increasing psychological burden on patients and their families. As vision 
worsens, patients experience increasing psychological burden, along with a growing fear of 
blindness, social withdrawal from impaired vision, and depression.19  
 
This study confirms previous findings that OAG is a chronic disease which incurs substantial 
annual costs that increase over time as the disease progresses.19,20 Inadequate treatment results in 
disease progression, leading to appreciable increases in resource utilization, costs for end-stage 
therapy and indirect costs.21,22 A medication regimen typically continues for the rest of a patient's 
life. The successful management of a patient's glaucoma, in terms of slowing the disease 
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progression, is dependent on the patient's ability to adhere to the recommended medication 
regimen and to persist with the therapy. In fact, recent research has shown that up to 90% of 
patients after 12 months in the United States are non-adherent with their ocular hypotensive drug 
therapies.23 The challenge with adherence has been documented in the literature, and is due to 
inability to properly administer eye drops, cost considerations, and a lack of awareness of the 
slow but gradual loss of vision. Studies have shown that poor medication adherence is associated 
with worsening glaucoma. Progression rates, despite primarily medical treatment from landmark 
long-term longitudinal studies, are available and ranges up to 50% over 5 years or longer.24 This 
highlights the difficulty with medical adherence and the inadequacy of medical treatment to 
maintain patients in a safe IOP zone.  Finally, caution is warranted when attempting to generalize 
these study findings to patients with other forms of glaucoma, those without health insurance, 
those outside of the United States, and patients who don’t have access to iStent or SLT as 
variables may differ considerably from those used in the model for these groups.  
    
Conclusion 
This analysis shows that despite higher costs in year zero, annual costs thereafter were lowest in 
the two-stent treatment arm and showed savings compared to the medications only and SLT 
treatment arms.  Two-stent treatment may reduce OAG-related health resource use, leading to 
direct savings, especially when compared to medications only and at longer time horizons. 
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Tables with captions (on individual pages): 
Table 1. Percentage of Uncontrolled OAG Patients Receiving Therapies 
 
Abbreviations: OAG, open angle glaucoma; SLT, selective laser trabeculoplasty. 
Treatment patterns informed by a panel of clinicians experienced in the treatment of glaucoma patients with uncontrolled intraocular 
pressure. 
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Table 2. Use of concurrent and standalone medications 
Number of concurrent 
medicationsa 
Types of medicationsb,c 
0 N/A 
1 Prostaglandin 
2 75% prostaglandin and beta-blocker 
or 
25% prostaglandin and (CAI/AAA)d 
3 prostaglandin and beta-blocker and AAA/CAIe 
4 prostaglandin and 2 meds combof and (CAI or AAA) 
Abbreviations: SLT, selective laser trabeculoplasty; CAI, carbonic anhydrase inhibitors; AAA, 
alpha-2 agonists. 
a During each cycle, a patient being treated with medications-only was expected to receive 2-4 
medications, and a patient being treated with iStents, SLT, or filtering surgery treatments 
was expected to receive 0-4 medications. 
b Prostaglandins = bimatoprost, travoprost, or latanoprost. 
c Beta-blockers = timolol maleate. 
d brimonidine tartrate / brinzolamide 
e brimonidine tartrate / Dorzolamide HCl 
f Combination AAA plus beta-blocker or Combination CAI plus beta-blocker 
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Table 3. Inputs 
Input Basecase 
Value 
Source Sensitivity Analysis 
Low High  Reason 
Treatment costs         
Medications a         
1 medication $495.01  2016 RED BOOK, 2014 IMS prescriptions 
data; 11-13 
$371.26  $618.76  ±25% 
2 medications $960.66  2016 RED BOOK, 2014 IMS prescriptions 
data; 11-13 
$720.50  $1,200.83  ±25% 
3 medications $1,020.04  2016 RED BOOK, 2014 IMS prescriptions 
data; 11-13 
$765.03  $1,275.05  ±25% 
4 medications $2,086.41 2016 RED BOOK, 2014 IMS prescriptions 
data; 11-13 
$1,564.81  $2,608.01  ±25% 
Procedures a          
iStent procedure $2,711.27  OPPS LDS 2016, manufacturer sales data on 
file 
$2,033.45  $3,389.09  ±25% 
SLT $396.39  OPPS LDS 2016 $297.29  $495.49  ±25% 
Filtering surgery $3,783.32  OPPS LDS 2016, 2013 CMS claims data $2,837.49  $4,729.15  ±25% 
Complications b          
1st following year          
iStent procedure $0.00  Fea et al. Clin Ophthalmol 201414; Vold et 
al. AGS annual meeting 2015 Abstract ID 
3916 
$0.00  $510.69  $0, $(50% surgery 
complication) 
SLT $0.00  Realini et al. JAMA Ophthalmol 201315 $0.00  $510.69  $0, $(50% surgery 
complication) 
Filtering surgery $1021.38  2013 CMS claims data $766.04  $1,276.73  ±25% 
All other subsequent years      
 
  
iStent procedure $0.00  Fea et al. Clin Ophthalmol 201414; Vold et 
al. AGS annual meeting 2015 Abstract ID 
3916 
$0.00  $181.69 $0, $(50% surgery 
complication) 
SLT $0.00  Realini et al. JAMA Ophthalmol 201315 $0.00  $181.69  $0, $(50% surgery 
complication) 
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Input Basecase 
Value 
Source Sensitivity Analysis 
Low High  Reason 
Filtering surgery $363.37  2013 CMS claims data $272.53  $454.21  ±25% 
Annual time preference 
discount rate 
3.0%  1.0% 5.0% ISPOR guidelines18 
Abbreviations: SLT, selective laser trabeculoplasty; OPPS LDS, Outpatient Prospective Payment System Limited Data Set; CMS, 
Centers for Medicare and Medicaid Services; ISPOR, International Society for Pharmacoeconomics and Outcomes Research. 
a Applied once in the cycle during which treatment is received. 
b Annual costs applied during cycles subsequent to receiving treatment. 
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Table 4. Annual marginal costs 
Initial 
treatment 
Year Average per follow- 
up year (1-5) 0 1 2 3 4 5 
Medications 
only $996 $1,065 $1,055 $1,044 $1,033 $1,022 $1,044 
SLT $842 $691 $740 $783 $814 $860 $777 
iStent procedure $2,810 $217 $290 $343 $358 $401 $322 
Abbreviation: SLT, selective laser trabeculoplasty. 
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Table 5. Inputs uncertainty most influencing 5-year cumulative cost outcomes 
Influential 
input 
order 
Cumulative costs by initial treatment arm Cumulative cost difference 
iStent 
procedure SLT 
Medications-
only 
iStent 
procedure vs 
SLT 
iStent 
procedure vs 
medications 
only 
1 Cost of the iStent procedure 
Cost of 
medications 
Cost of 
medications 
Cost of the 
iStent procedure 
Cost of 
medications 
2 Cost of medications 
Probability of 
downstream 
procedures in 
the SLT arm 
Time preference 
discount 
Cost of 
medications 
Cost of the 
iStent procedure 
3 
Probability of 
downstream 
procedures in 
the iStent 
procedure arm 
Time 
preference 
discount 
Probability of 
downstream 
procedure in the 
medications-
only arm 
Probability of 
downstream 
procedures in 
the SLT arm 
Probability of 
downstream 
procedures in 
the iStent 
procedure arm 
4 
Cost of iStent 
procedure 
complications 
Cost of SLT Cost of filtering surgery 
Probability of 
downstream 
procedures in 
the iStent 
procedure arm 
Cost of iStent 
procedure 
complications 
5 Time preference discount 
Cost of SLT 
complications 
Cost of SLT 
complications 
Cost of iStent 
procedure 
complications 
Time preference 
discount 
Abbreviation: SLT, selective laser trabeculoplasty. 
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Figures 
Figure 1. Treatment transitions 
 
Transitions between treatments were modeled annually and were only permitted in the directions 
of the arrows. 
Rectangular blue boxes represent initiating treatments considered in year 0. Grey ovals 
represent downstream treatments considered in years 1-5. Blue arrows represent the first 
transitions after the first model cycle (in year 0), and gray arrows represent downstream 
treatment transitions in subsequent cycles (years 1-5). 
Abbreviations: SLT, selective laser trabeculoplasty. 
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Figure 2. Cumulative costs of treatments over 5 years 
 
Abbreviation: SLT, selective laser trabeculoplasty. 
  
0 1 2 3 4 5
Medications only $996.29 $2,061.66 $3,117.08 $4,161.50 $5,194.92 $6,217.08
SLT $841.90 $1,532.51 $2,272.77 $3,055.75 $3,869.65 $4,729.85
iStent procedure $2,810.27 $3,027.70 $3,318.17 $3,661.20 $4,018.93 $4,420.38
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Figure 3. Tornado diagram 
A. Incremental 5-year costs difference with the iStent procedure compared to SLT 
 
 
 
B. Incremental 5-year costs difference with the iStent procedure compared to medications 
only 
 
 
Abbreviation: SLT, selective laser trabeculoplasty. 
Dotted vertical line represents the basecase result. 
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Figure captions (as a list): 
Figure 1. Treatment transitions 
Figure 2. Cumulative costs of treatments over 5 years 
Figure 3. Tornado diagram 
 
Supplementary material: 
None 
 
